Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases | MicrobiomeTrials
Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2021-08-04Est. Completion: 2026-09
Enrollment target: 50 participants
Locations
Octapharma Research Site, Irvine, California, United States
Octapharma Research Site, Centennial, Colorado, United States
Octapharma Research Site, Port Saint Lucie, Florida, United States
Octapharma Research Site, St. Petersburg, Florida, United States
Octapharma Research Site, Chicago, Illinois, United States
Octapharma Research Site, Overland Park, Kansas, United States
Octapharma Research Site, Louisville, Kentucky, United States
Octapharma Research Site, White Marsh, Maryland, United States
Octapharma Research Site, Kansas City, Missouri, United States
Octapharma Research Site, Omaha, Nebraska, United States
Octapharma Research Site, Leipzig, Germany
Octapharma Research Site, Munich, Germany
Octapharma Research Site, Budapest, Hungary
Octapharma Research Site, Debrecen, Hungary
Octapharma Research Site, Naples, Italy
Octapharma Research Site, Roma, Italy
Octapharma Research Site, Roma, Italy
Octapharma Research Site, Treviso, Italy
Other microbiome trials you might be interested in